Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Drug price regulator...

    Drug price regulator finds 4,700 medicines illegally over-priced

    Written by savita thakur thakur Published On 2016-02-26T13:36:20+05:30  |  Updated On 26 Feb 2016 1:36 PM IST
    New Delhi: The national drug price regulator NPPA has warned of action against companies violating its pricing norms as it found prices of more than 4,700 medicines had increased beyond permissible limits.

    Although over 95 per cent of stock keeping units of medicines were found to be complying with its order during an internal study.

    According to the National Pharma Pricing Regulator (NPPA), of the 1,01,418 pharma stock keeping units observed, prices of 4,724 SKUs were found to have changed beyond permissible limit as per Drug Prices Control Order (DPCO) 2013.

    It further said prices of 17,226 SKUs rose within the permissible limit as per as DPCO 2013.

    While prices of 18,104 SKUs declined, there was no change in those of 60,998 SKUs as per the study conducted by NPPA in August last year. It found that 95.4 per cent of SKUs complied with the DPCO, 2013 from pricing perspective.

    "After ascertaining status in respect of the cases observed for price violation from the manufacturers concerned, NPPA will take necessary action in such cases where price violation has been established under provisions of DPCO 2013," NPPA said.

    The drug price regulator said out of the 4,724 SKUs, the prices of which have gone up in violation of the DPCO, 2013, 829 were scheduled SKUs while 3,895 were unscheduled SKUs.

    Out of the total SKUs studied, 12,213 were scheduled SKUs while 88,811 were in the non-scheduled category, NPPA said.

    NPPA's mandate is to fix/ revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
    drug priceDrug Prices Control Orderillegally over price medicineNational Pharma Pricing Regulator authorityNPPA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok